Retatrutide's triple GLP-1/GIP/glucagon mechanism produces significantly greater weight loss than semaglutide (Wegovy) in Phase 3 trials. Here is the complete comparison.
Retatrutide activates GLP-1, GIP, and glucagon receptors. Wegovy (semaglutide) activates only GLP-1 receptors. This triple mechanism drives greater energy expenditure and hepatic fat mobilization, producing approximately 9 percentage points more weight loss in Phase 3 trials. Retatrutide is not yet FDA-approved.
| Feature | Retatrutide | Wegovy (Semaglutide) |
|---|---|---|
| Active molecule | Retatrutide | Semaglutide |
| Mechanism | Triple GLP-1 + GIP + Glucagon agonist | GLP-1 receptor agonist only |
| Brand name (Rx) | None yet — Phase 3 trials | Wegovy (obesity), Ozempic (diabetes) |
| Avg weight loss (Phase 3) | ~24.2% body weight | ~14.9% body weight (STEP-1) |
| GLP-1 activity | Full GLP-1 agonist | Full GLP-1 agonist |
| GIP activity | Full GIP agonist | None |
| Glucagon activity | Full glucagon agonist | None |
| FDA approval | Not yet approved (Phase 3) | Approved 2021 |
| Dosing frequency | Once weekly | Once weekly |
| Cardiovascular data | Phase 3 ongoing | SELECT trial (2023) — 20% CV risk reduction |
Phase 3 data shows retatrutide produces significantly greater weight loss than semaglutide (Wegovy) — approximately 24.2% vs 14.9% body weight. Retatrutide's triple GLP-1/GIP/glucagon mechanism drives greater energy expenditure. However, Wegovy has more published cardiovascular outcome data (SELECT trial, 2023).
Wegovy contains semaglutide, a GLP-1 receptor agonist. Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. The additional GIP and glucagon receptor agonism in retatrutide enhances insulin sensitization and energy expenditure beyond what semaglutide alone achieves. Retatrutide is not yet FDA-approved.
Phase 3 data shows approximately 24.2% body weight reduction with retatrutide vs 14.9% with semaglutide (Wegovy) — a difference of roughly 9 percentage points. At a body weight of 250 lbs, this translates to approximately 60 lbs vs 37 lbs of weight loss.
Retatrutide is currently in Phase 3 clinical trials. FDA approval is anticipated in 2026-2027 pending trial completion and regulatory review. It is currently available as a research peptide.
Retatrutide and semaglutide have similar GI side effect profiles (nausea, vomiting, diarrhea) in Phase 3 data. Retatrutide's glucagon agonism may increase heart rate more than semaglutide. Long-term cardiovascular safety data for retatrutide is still being collected in ongoing trials.
Purgo Labs carries both retatrutide and semaglutide with third-party COAs. Use code HEALTH for 15% off.
Shop at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.